HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Entrada stock falls on Duchenne data; Wegovy expands access

Plus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...

By Endpoints News · May 7, 2026 · via Endpoints News
Entrada stock falls on Duchenne data; Wegovy expands access

Image: Endpoints News

This is an aggregated industry headline. Read the full story at Endpoints News →

Tags
pipelineformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
PipelineFiercePharma ↗
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same sin…
May 10, 2026
Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis
PipelineFierceBiotech ↗
Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis
Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short of expectations, crashing the bi…
May 9, 2026
Cytokinetics’ Myqorzo Delivers Landmark Phase 3 Win in Non‑Obstructive HCM
PipelineBriefing
Cytokinetics’ Myqorzo Delivers Landmark Phase 3 Win in Non‑Obstructive HCM
By succeeding in the ACACIA-HCM trial, Myqorzo could become the first approved treatment for non‑obstructive h…
May 6, 2026